Application of Nanotechnology in the Targeted Release of Anticancer Drugs in Ovarian Cancer Treatment

摘要

Initial study was performed which was localized MagNaGel nanoparticles in an orthotopic ovarian cancer mouse model by MRI and also via IVIS imaging techniques. Mice were injected intraperitoneally with ovarian cancer cells tagged with luciferase gene. Tumor growth was monitored using both a 4.7T small animal MRI and IVIS Imaging system. Once tumor and ascites developed in the mice, cisplatin-loaded MagNagel particles with 10.0 nm IO core were injected into the tail-vein (IV) of the cancer bearing mice or intraperitoneally (IP) depending on the group. After set time periods, MRI and IVIS imaging was performed on the mice. Organs were harvested and drug levels determined in biodistribution studies comparing untargeted and targeted particles. Survival studies were performed using IP injected nanoparticles. Biodistribution studies confirmed high levels of the nanoparticle in the spleen and liver but without release of cisplatin in blood. Survival studies in IP treated mice did not show a survival advantage for the either untargeted or targeted (HER-2neu) nanoparticles. Further study with IV injections and with different particle formulations and targeting agents is necessary.